Interim results from The Chocolate Bar Registry conducted in the United States demonstrate that use of the Chocolate PTA balloon achieved high rates of treatment success and limb preservation in patients with peripheral arterial disease.

April 23, 2014 — The PROCEED II heart transplant U.S. Food and Drug Administration (FDA) pivotal trial results using the Organ Care System (OCS) Heart platform were announced at the International Society for Heart and Lung Transplantation (ISHLT) 34th annual meeting and scientific sessions in San Diego.

April 23, 2014 — Philips Healthcare has completed its first field study for its Minicare handheld cardiac Troponin-I (cTn-I) blood test, demonstrating the platform’s potential to produce lab-equivalent results with finger prick samples within minutes. The initial results are encouraging as Philips prepares for the Minicare cTn-I system’s clinical trial, scheduled for 2015.

Loyola University Medical Center is now offering patients the most advanced positron emission tomography/computed tomography (PET/CT) scanner on the market.

April 21, 2014 — Decision Resources Group announced in a report that Servier's ivabradine (procoralan) is set to become the clinical gold standard in the treatment of chronic heart failure (CHF). Already available in Europe, where it has enjoyed moderate use in CHF and stable angina patients, ivabradine's clinical profile could prime this agent for a potentially successful launch in the United States, where Amgen own the marketing rights to procoralan.

Providence Saint Joseph Medical Center in Burbank, Calif., is the first hospital in the nation to conduct a magnetic resonance imaging (MRI) scan of a patient implanted with a new MRI-compatible pacemaker — a breakthrough because metal implants often exclude patients from this imaging because of the strong magnetic force.

Tendyne Holdings Inc. has secured $25 million in an oversubscribed Series C financing led by Apple Tree Partners, along with Boulle Group members and other existing investors.